The Medical Letter on Drugs and Therapeutics
Venetoclax (Venclexta) for Chronic Lymphocytic Leukemia
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

The FDA has approved venetoclax (Venclexta – Abbvie/Genentech), an oral selective BCL-2 inhibitor, for treatment of chronic lymphocytic leukemia (CLL) in patients with a 17p deletion who have received at least one prior therapy. The 17p deletion is associated with a poor prognosis in patients with CLL1,2; it is prevalent in about 20% of patients with relapsed CLL. Venetoclax is the first BCL-2 inhibitor to become available in the US.

MECHANISM OF ACTION — BCL-2 is an antiapoptotic protein that is overexpressed in many CLL cells. Overexpression of BCL-2 increases tumor cell survival and is associated with increased resistance to chemotherapy. Venetoclax binds directly to BCL-2 and has induced apoptosis in vitro in tumor cells that overexpress BCL-2.

CLINICAL STUDIES — A total of 116 patients with relapsed or refractory CLL or ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Venetoclax (Venclexta) for Chronic Lymphocytic Leukemia
Article code: 1500d
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian